"The Evaluation of Stimulant Withdrawal"
| Status: | Withdrawn |
|---|---|
| Conditions: | Anxiety, Anxiety, Psychiatric, Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 2/2/2019 |
| Start Date: | July 1, 2007 |
| End Date: | June 30, 2011 |
Scientific Component IV: Pharmacotherapy to Prevent Methamphetamine Relapse
The purpose of this research study is to determine whether Carvedilol, an FDA approved beta
blocker, when administered for an 8-week period to veterans currently undergoing treatment
for methamphetamine dependence (1) improves their ability to stay in treatment longer,
(2)eases the aversive symptoms that accompany stimulant withdrawal, and (3) increases the
time they remain abstinent from methamphetamine.
blocker, when administered for an 8-week period to veterans currently undergoing treatment
for methamphetamine dependence (1) improves their ability to stay in treatment longer,
(2)eases the aversive symptoms that accompany stimulant withdrawal, and (3) increases the
time they remain abstinent from methamphetamine.
Inclusion Criteria:
- Must have entered treatment into the outpatient Clinical Addiction Rehabilitation
Section (CARS) through the US Portland Veterans Affairs Medical Center
- Must meet the clinical definition for methamphetamine dependence
- Self-reported methamphetamine use within 10 days of entering the study
- Must be able to understand and sign the consent form
Exclusion Criteria:
- Dependent on any other drug except nicotine, caffeine, marijuana and alcohol
- Pregnant or nursing mothers
- Psychosis
- Dementia
- Any serious medical condition that could be aggravated by the study protocol (Allergic
reaction, Hypotension, Asthma, Bronchospastic conditions, Angina, Bronchitis,
Emphysema, Bradycardia, Heart or blood vessel disease, Diabetes mellitus, Low blood
sugar, Kidney disease, Liver disease or Overactive thyroid)
- History of withdrawal seizures or delirium tremors
- Use of MAO inhibitors within the last two weeks
- Considerable hepatocellular injury, including cirrhosis of the liver or liver function
test levels higher than 2 times normal
We found this trial at
1
site
Click here to add this to my saved trials
